Analyst Ratings for SpringWorks Therapeutics
Within the last quarter, SpringWorks Therapeutics (NASDAQ:SWTX) has observed the following analyst ratings:
HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $94
HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and lowers the price target from $95 to $94.
SpringWorks Therapeutics To Present Progress Across Company’s Targeted Oncology Portfolio At Virtual R&D Day
-- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA's Real-Time Oncology Review (RTOR) Program, Expected in Second Half of 2022 --
-- New Phase 2 Study Announced to Evaluate
HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $95
HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and lowers the price target from $142 to $95.
70 Biggest Movers From Friday
Gainers
Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
Mid-Afternoon Market Update: Dow Gains 500 Points; Red Robin Gourmet Burgers Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 500 points on Friday.
Mid-Day Market Update: Nasdaq Jumps 300 Points; Aurora Cannabis Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping around 300 points on Friday.
41 Stocks Moving In Friday’s Mid-Day Session
Gainers
Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares rose 60.2% to $1.7136. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.